Multidrug resistance protein (MRP) 4- and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl)adenine by microglia

Shannon Dallas1, Lyanne Schlichter, Reina Bendayan

  • 1Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, 19 Russell St., Toronto, ON M5S 2S2, Canada.

Insights

Microglia in HIV-1 infection express multiple drug efflux transporters, including MRP4 and MRP5. These transporters may limit antiretroviral drug entry into brain cells, impacting HIV-associated dementia treatment.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Microglial activation is central to HIV-associated dementia pathogenesis.
  • Microglia express ATP-dependent efflux transporters like MRP1 and P-gp.
  • The role of other MRP family members in microglia remains unclear.

Purpose of the Study:

  • To investigate the expression of rMRP4 and rMRP5 in rat microglia.
  • To characterize the transport of a prodrug (bis(POM)PMEA) and its metabolite (PMEA) in microglia.
  • To determine if these transporters affect antiretroviral drug penetration in the brain.

Main Methods:

  • Reverse transcriptase-polymerase chain reaction (RT-PCR) for mRNA detection.
  • Western blot analysis for protein expression confirmation.
  • Thin layer chromatography and radiolabeling to study drug transport in MLS-9 microglia cell line.

Main Results:

  • Rat microglia and MLS-9 cells express rMRP4 and rMRP5 mRNA and proteins.
  • Bis(pivaloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine (bis(POM)PMEA) is converted to 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in MLS-9 cells.
  • PMEA efflux is ATP-dependent, inhibited by MRP inhibitors and azidothymidine-monophosphate, suggesting MRP4/5 involvement.

Conclusions:

  • Microglia express multiple ATP-binding cassette transporters, including P-gp, MRP1, MRP4, and MRP5.
  • These transporters can restrict the permeation of various antiretroviral drugs into brain cells.
  • Understanding these efflux mechanisms is crucial for developing effective HIV-1 therapies for the central nervous system.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Export of Misfolded Proteins out of the ER01:32

Export of Misfolded Proteins out of the ER

After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...